Parkinson's Disease

The latest sourced reporting on Parkinson's Disease from Dementias Today: dated, and plain about what the evidence does and does not show.

The chart is the patient now, and software has started reading it

A narrative review published on October 20 inventories where generative AI already touches Alzheimer's work. The uses furthest along are the ones no family ever sees: synthetic notes, phenotype mining from visit records, and drafted summaries. None of it has been tested in a live clinic.

The Side Effect That Starts With a Sentence

A systematic review from the University of Leicester, published in Frontiers in Psychiatry on 8 May 2026, gathered thirteen experiments in which negative expectation was deliberately switched on in people living with long-term conditions. The symptoms that followed were real. What the review cannot tell you is what that means for a family managing dementia medicines.

AR/ML Tool Flagged All Confirmed PD-MCI Cases in 21-Person Pilot

A small feasibility study paired a 10-minute augmented reality and machine learning tablet test with clinician assessments in Parkinson's disease, catching every case of mild cognitive impairment that specialists confirmed but also flagging nearly half the group who did not have it.

Wearable heart monitor shows distinct signal in Parkinson's disease, small study finds

A case-control study using a wearable ECG device found that several measures of heart rate variability were reduced in people with Parkinson's disease, and that one measure, low-frequency power, tracked tremor severity and correlated with brain volume on MRI. The pattern is different from the Alzheimer's-linked HRV changes reported earlier in this section, and the authors say it needs testing in far larger groups before it could serve as any kind of diagnostic tool.

The cells that stopped dividing and started shouting

A new synthesis from Barcelona and London argues that brain aging is driven not only by misfolded protein, but by cells that have quit the cell cycle and will not stop signalling. It is a review, not a discovery, and the human evidence is still thin.

The brain runs on a handshake, and ageing loosens the grip

A peer-reviewed narrative review in Mechanisms of Ageing and Development argues that the ageing brain fails as a partnership, not as a single cell type: neurons, astrocytes, oligodendrocytes and microglia trading energy under the control of mitochondrial fission, fusion and mitophagy. It is a framework, not a finding, and it rests largely on animal and cell work.

Trial Tests Whether Telling Volunteers the Truth Can Blunt Nocebo Pain

A Dutch laboratory trial found that openly telling healthy volunteers a device could not hurt them, paired with a symptom-reversing procedure, eased artificially induced pain sensitivity as well as or better than concealing that information. The method has not been tested in patients, older adults, or anyone with a dementia.

When Blood Sugar Meets Iron: A New Route to Dopamine Neuron Death

A Chinese team combined genetic analysis in people with experiments in mice and cells to argue that post-meal glucose spikes push dopamine neurons toward ferroptosis, an iron-dependent form of cell death. The human half of the evidence is genetic and indirect; the mechanism half is entirely animal and laboratory work.

The Alzheimer's twin that does not exist yet has a blueprint

A preprint from Regensburg, Aachen, Amsterdam and Imperial College London sets out how scans, blood markers and everyday speech could feed one patient-specific simulation. No patient has been through it, and the authors say bedside use comes last.

Twenty Percent Of You, Spent On Thinking

A review published online in Neurobiology of Disease on 23 September 2026 maps how neurons, astrocytes, oligodendrocytes, microglia and the brain's blood vessels split a very small energy budget, and argues that the breakdown of that split comes early in neurodegeneration, with neuronal loss as a late line in the account. It is a synthesis of work already published, with no new patient data.

Before the Drug, Someone Has to Build the Starting Line

Nine centres across North America are enrolling people whose dreams turn physical. There is no medicine in this study. Its purpose is to assemble the cohort that a future neuroprotection trial would need, and the scaffolding is the point.

The package that has to find the basement

An open-access review in Advanced Healthcare Materials catalogues the nanoparticles engineered to carry drugs all the way to failing mitochondria in neurodegeneration, and states on its own first pages that none has been approved for anyone.

Exeter's Dementia Policy Unit Wins Two More Years, and a Wider Brief

The National Institute for Health and Care Research has extended its Policy Research Unit at the University of Exeter with 2 million pounds and two extra years, stretching its mandate past dementia and neurodegeneration to cover more of the neurological conditions families live with.

A Parkinson's Trial Bets on the Cell's Own Cleanup Crew

Mission Therapeutics has dosed the first Parkinson's patient in a Phase 1b trial of MTX325, an oral drug designed to help brain cells clear out damaged mitochondria, a mechanism distinct from the amyloid and alpha-synuclein targets most other experimental drugs pursue, according to a new ClinicalTrials.gov registration and a company disclosure.

The shadow by the door belongs to nobody

DemMA, published in the Findings of ACL 2026, puts a simulated person with dementia in the chair so trainees can practise the conversation: nine subtypes, nonverbal cues, 2,709 synthetic dialogues, and not one real patient in the data.

A Gut Signal in Parkinson's Crosses an Ocean, and Mostly Holds Up

A study of 42 Parkinson's patients in Fujian province found its own pattern of gut bacterial imbalance, the first look at this population and a check on whether a gut signature reported this year in Europe, the US, South Korea and Turkey shows up in people living on the other side of the world.

PAHO Finds Long-Term Care Policy Has Outpaced Financing Across the Americas

A regional midterm review of the UN Decade of Healthy Aging finds that the share of countries in the Americas with a national long-term-care policy jumped from 61 percent to 88 percent since 2020, but the money and services to make those policies real have not kept pace, with direct consequences for how dementia care gets funded and staffed.

Thirty-Year US Death Data Give Parkinson's Mortality a Forward Projection to 2030

A national review of 1.15 million Parkinson's-related death certificates filed from 1999 through 2025 finds that the overall age-adjusted mortality rate did not change significantly over the full period, and that most of the apparent decline since 2021 traces to the fading effect of COVID-19 being listed alongside Parkinson's on death certificates, not to any improvement in underlying mortality.

Antibody Targeting a Sugar-Binding Immune Protein Advances to Phase 2 in Parkinson's Disease

TrueBinding's TB006, an antibody against galectin-3, has entered a placebo-controlled Phase 2a trial in early Parkinson's disease, according to its federal registration. The approach targets neuroinflammation rather than the alpha-synuclein clumping or kinase pathways most late-stage Parkinson's drugs pursue, and no human efficacy data in Parkinson's disease exist yet.

Tau's escape route out of the lysosome, and the crew that tries to seal it

A new preprint from a Berkeley structural biology lab used cryo-electron tomography on cultured neurons and astrocytes and found no evidence that tau fibrils tear their way out of lysosomes. The compartments stayed intact. The leak, the authors argue, is something subtler. This is laboratory cell work, not peer reviewed, and not a treatment.

Under the TMS coil: a Parkinson's trial puts Ayurveda on the record

At a national neurosciences institute in Bengaluru, an exploratory randomized trial is adding a 180-day Ayurvedic regimen to optimized standard Parkinson's care, then measuring cortical excitability, heart-rate variability, cytokines and telomere length. The protocol is now published. The results are not.

New Model Proposes Molecular Steps Behind Lewy Body Formation

A laboratory study in Communications Biology reports that disease-linked chemical changes expose a normally hidden sticky region of alpha-synuclein, letting it grab other proteins indiscriminately, a mechanism the authors call a 'Multifactorial Random Disorder Model.'

Trial pairs two dopamine-making genes in one brain infusion for Parkinson's

A phase 1 study delivered a single viral vector carrying both tyrosine hydroxylase and AADC genes into the striatum, aiming for cells that manufacture dopamine on their own rather than depending on oral levodopa. Twelve-month safety data are now published; the trial was not designed to prove the therapy works.